$8.70
1,092.11% yesterday
Nasdaq, Dec 03, 10:15 pm CET
ISIN
US8693671021
Symbol
STRO

Sutro Biopharma, Inc. Stock price

$8.70
-2.30 20.91% 1M
-0.43 4.74% 6M
-9.70 52.72% YTD
-18.90 68.48% 1Y
-65.20 88.23% 3Y
-161.30 94.88% 5Y
-143.30 94.28% 10Y
-143.30 94.28% 20Y
Nasdaq, Closing price Wed, Dec 03 2025
+1.40 19.21%
ISIN
US8693671021
Symbol
STRO
Industry

Key metrics

Basic
Market capitalization
$621.3m
Enterprise Value
$453.7m
Net debt
positive
Cash
$167.6m
Shares outstanding
85.1m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
5.9 | 6.1
EV/Sales
4.3 | 4.4
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
11.5%
Return on Equity
-510.0%
ROCE
-98.9%
ROIC
-528.9%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$105.7m | $102.7m
EBITDA
$-128.7m | $-106.6m
EBIT
$-136.3m | $-139.1m
Net Income
$-216.3m | $-167.9m
Free Cash Flow
$-225.4m
Growth (TTM | estimate)
Revenue
-34.4% | 65.5%
EBITDA
-4.4% | 53.9%
EBIT
-4.5% | 41.7%
Net Income
-74.2% | 26.2%
Free Cash Flow
-106.0%
Margin (TTM | estimate)
Gross
-
EBITDA
-121.9% | -103.8%
EBIT
-129.0%
Net
-204.8% | -163.5%
Free Cash Flow
-213.3%
More
EPS
$-2.5
FCF per Share
$-2.6
Short interest
4.0%
Employees
310
Rev per Employee
$200.0k
Show more

Is Sutro Biopharma, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,088 stocks worldwide.

Sutro Biopharma, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

16 Analysts have issued a Sutro Biopharma, Inc. forecast:

10x Buy
63%
5x Hold
31%
1x Sell
6%

Analyst Opinions

16 Analysts have issued a Sutro Biopharma, Inc. forecast:

Buy
63%
Hold
31%
Sell
6%

Financial data from Sutro Biopharma, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
106 106
34% 34%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 41 41
25% 25%
39%
- Research and Development Expense 201 201
14% 14%
190%
-129 -129
4% 4%
-122%
- Depreciation and Amortization 7.57 7.57
7% 7%
7%
EBIT (Operating Income) EBIT -136 -136
4% 4%
-129%
Net Profit -216 -216
74% 74%
-205%

In millions USD.

Don't miss a Thing! We will send you all news about Sutro Biopharma, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Sutro Biopharma, Inc. Stock News

Neutral
Seeking Alpha
22 days ago
Sutro Biopharma, Inc. ( STRO ) Discusses Strategic Reset and Progress in Next-Generation ADC Pipeline and Platform Innovation November 12, 2025 10:00 AM EST Company Participants Jane Chung - CEO & Director Jonathan Fawcett Anthony Tolcher Hans-Peter Gerber - Chief Scientific Officer Conference Call Participants Tara Bancroft - TD Cowen, Research Division Edward Tenthoff - Piper Sandler & Co., R...
Neutral
GlobeNewsWire
28 days ago
– Company announces U.S. FDA clearance of Investigational New Drug (IND) application for STRO-004, its potential best-in-class Tissue Factor ADC; Expects to dose first patient before year-end –
Neutral
GlobeNewsWire
29 days ago
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that it will host a virtual Research & Development Day, highlighting the details of its platform innovation and next-generation ADC pipeline.
More Sutro Biopharma, Inc. News

Company Profile

Sutro Biopharma Inc. engages in the drug discovery, development, and manufacturing of pharmaceutical products. It focuses on next generation cancer and autoimmune therapeutics. The company was founded by James R. Swartz and Sutanto Widjaja on April 21, 2003 and is headquartered in South San Francisco, CA.

Head office United States
CEO Jane Chung
Employees 310
Founded 2003
Website www.sutrobio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today